A drug candidate, an anti-FGFR1 humanized antibody, offers fresh approach to battling aggressive lung cancer
Dr. Ilya Tsimafeyeu's team found that an antibody blocking the FGFR1 receptor shrank lung tumours in animal models and strengthened the effect of existing immunotherapy drugs.










